● Recruiting

Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies

Condition: Acute Lymphocytic Leukemia (ALL) · Acute Myeloid Leukemia (AML) · Acute Leukemia · Sponsor: Sawa Ito, MD

PhasePhase 1

Planned participants48

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This phase 1 trial will investigate the safety and effectiveness of Thiotepa, Busulfan, and Fludarabine (TBF) conditioning regimen with post-transplant cyclophosphamide (PTCy) in HLA-matched related or unrelated donor allogeneic stem cell transplantation (alloSCT).

This description comes directly from the study's public registry record.

Talk to the study team

Amy Rogers, RN, BSN · 412-623-4036 · rodgera@upmc.edu

Linda Elias, RN, BSN · 412-623-6037 · eliaslj@upmc.edu

Always discuss trial participation with your own doctor first.

Locations (1)

UMPC Hillman Cancer Center

Pittsburgh, Pennsylvania, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07565220